
Louis P. Garrison Jr, PhD1,*, Peter J. Neumann, ScD2, Richard J. Willke, PhD3, Anirban Basu, PhD4, Patricia M. Danzon, PhD5, Jalpa A. Doshi, PhD6, Michael F. Drummond, MCom, DPhil7, Darius N. Lakdawalla, PhD8, Mark V. Pauly, PhD9, Charles E. Phelps, PhD, MBA10, Scott D. Ramsey, MD, PhD11, Adrian Towse, MPhil, MA12, Milton C. Weinstein, PhD11

1Pharmaceutical Outcomes Research and Policy Program, The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Seattle, WA, USA; 2Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA, USA; 3International Society for Pharmacoeconomics and Outcomes Research, Lawrenceville, NJ, USA; 4Health Care Management, The Wharton School, University of Pennsylvania, Philadelphia, PA, USA; 5Division of General Internal Medicine, University of Pennsylvania, Philadelphia, PA, USA; 6Centre for Health Economics, University of York, York, UK; 7Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, CA, USA; 8Economics, Public Health Sciences, Political Science, University of Rochester, Guelph, CA, USA; 9Department of General Internal Medicine, University of Washington, Seattle, WA, USA; 10Office of Health Economics, London, UK; 11Health Policy and Management, Harvard University, Boston, MA, USA

A B S T R A C T

This summary section first lists key points from each of the six sections of the report, followed by six key recommendations. The Special Task Force chose to take a health economics approach to the question of whether a health plan should cover and reimburse a specific technology, beginning with the view that the conventional cost-per-quality-adjusted life-year metric has both strengths as a starting point and recognized limitations. This report calls for the development of a more comprehensive economic evaluation that could include novel elements of value (e.g., insurance value and equity) as part of either an ‘augmented’ cost-effectiveness analysis or a multicriteria decision analysis. Given an aggregation of elements to a measure of value, consistent use of a cost-effectiveness threshold can help ensure the maximization of health gain and well-being for a given budget. These decisions can benefit from the use of deliberative processes. The six recommendations are to: 1) be explicit about decision context and perspective in value assessment frameworks; 2) base health plan coverage and reimbursement decisions on an evaluation of the incremental costs and benefits of health care technologies as is provided by cost-effectiveness analysis; 3) develop value thresholds to serve as one important input to help guide coverage and reimbursement decisions; 4) manage budget constraints and affordability on the basis of cost-effectiveness principles; 5) test and consider using structured deliberative processes for health plan coverage and reimbursement decisions; and 6) explore and test novel elements of benefit to improve value measures that reflect the perspectives of both plan members and patients.

This summary section first lists key points from each of the six sections of the report, followed by six key recommendations. The Special Task Force chose to take a health economics approach to the question of whether a health plan should cover and reimburse a specific technology, beginning with the view that the conventional cost-per-quality-adjusted life-year metric has both strengths as a starting point and recognized limitations. This report calls for the development of a more comprehensive economic evaluation that could include novel elements of value (e.g., insurance value and equity) as part of either an ‘augmented’ cost-effectiveness analysis or a multicriteria decision analysis. Given an aggregation of elements to a measure of value, consistent use of a cost-effectiveness threshold can help ensure the maximization of health gain and well-being for a given budget. These decisions can benefit from the use of deliberative processes. The six recommendations are to: 1) be explicit about decision context and perspective in value assessment frameworks; 2) base health plan coverage and reimbursement decisions on an evaluation of the incremental costs and benefits of health care technologies as is provided by cost-effectiveness analysis; 3) develop value thresholds to serve as one important input to help guide coverage and reimbursement decisions; 4) manage budget constraints and affordability on the basis of cost-effectiveness principles; 5) test and consider using structured deliberative processes for health plan coverage and reimbursement decisions; and 6) explore and test novel elements of benefit to improve value measures that reflect the perspectives of both plan members and patients.

Keywords: augmented cost-effectiveness analysis, benefit-cost analysis, multi-criteria decision analysis, value frameworks.

Copyright © 2018, International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.

Preamble

During the course of this work of the Special Task Force (STF), we invited external input on two earlier versions of draft reports. The first draft report was sent to the STF’s External Advisory Board and Stakeholder Advisory Group on May 4, 2017. In response to feedback received, we posted a revised version to the full International Society for Pharmacoeconomics and Outcomes Research (ISPOR) membership on July 7, 2017.

These efforts resulted in many thoughtful and often detailed comments from a wide range of individuals representing diverse stakeholders, including patient organizations, payers, academic researchers, and the pharmaceutical and medical device industry.

Conflicts of interest: D. N. Lakdawalla is a consultant to Precision Health Economics and an investor in its parent company, Precision Medicine Group. The authors state that no ethical approval was needed. The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the agencies or organizations with which the authors are affiliated.

* Address correspondence to: Louis P. Garrison, Jr. The Comparative Health Outcomes, Policy, and Economics Institute, University of Washington, P.O. Box 357630, Seattle, WA 98195.

E-mail: lgarrisn@uw.edu

1098-3015/30.00 – see front matter Copyright © 2018, International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.

https://doi.org/10.1016/j.jval.2017.12.009
industries. The STF greatly appreciates this input and the final report is much improved because of it. We begin this final section with a summary of what we heard and how we responded.

Some reviewers praised the tenor and scope of the report and recommendations. Some underlined generally the need for more emphasis on transparency and stakeholder input into value framework methods and processes.

Many reviewers offered constructive criticism. A number of them emphasized that the report should be more “patient-centric.” Specifically, they emphasized that the patient perspective and patient voice needed to be reflected in all discussions about value—for example, that value measurement should consider patients’ personal goals and preferences for different treatment options.

Some commenters highlighted the shortcomings of the quality-adjusted life-year (QALY) metric, noting that QALYs often do not capture patient preferences well and potentially discount the value of an individual’s disability. Numerous reviewers addressed the STF’s recommendation regarding the use of the cost-per-QALY metric to inform public and private decision making. Some spoke in favor of this recommendation, although others cautioned that such use could impede access to important new treatments, and, more generally, argued that any overarching STF recommendations calling for payers to apply cost-per-QALY analyses and cost-effectiveness thresholds were not consonant with the pluralistic, market-based US health system. Some pointed out the US government’s own restrictions on the use of cost-per-QALY thresholds as evidence of the metric’s limitations and public opposition.

The STF considered each comment carefully as we revised the report, mindful of the diverse membership of ISPOR and the organization’s mission to advance good methods and informed decision making in pharmacoeconomics and outcomes research. Compared with earlier drafts, the final report contains more text on the importance of patient centricity, for example. In numerous places, we qualified language in response to feedback. We recognize that given the varied opinions of ISPOR members, not everyone will be satisfied with our judgments. Inviting the external commentaries that accompany the formal publication of this effort is one further attempt to ensure that diverse views are aired. The larger conversation about value metrics will undoubtedly continue on many fronts.

This summary section presents a list of key points from each of the six sections of our report, followed by a section listing our six key recommendations [1–6]. It is important to note that this report reviewed five recent US value assessment frameworks that differ by perspective and decision context. From a health economics perspective, the primary focus of our recommendations is on US payers—private and public. Broadly, our STF recommends greater use of cost-effectiveness analysis (CEA) in their decision making in order for them to best serve the interests of the plan members and patients who they represent. We also recognize, however, that there are challenges in applying CEA as well as a need for more research on the elements of value, on their aggregation, and on how they are used in deliberative decision making.

Introduction [1]

• Concerns about rising prescription drug prices have led to initiatives in the United States designed to measure and communicate the value of pharmaceuticals.
• Organizations promulgating value assessment frameworks differ in their missions, activities, and approaches.
• This section is based on the premise that value-based resource allocation decisions—about drugs and other health care technologies—should consider the full costs and benefits of decisions to relevant stakeholders and the decision contexts they face.
• We define “value” from an economic perspective in two related, but distinct senses: “gross value” is what individuals (or others acting on their behalf) would be willing to pay to acquire more health care or other goods or services. This has to be compared with the “opportunity cost” in terms of what benefits or other resources they are willing to forgo to obtain them. The difference between the two is the “net value.”
• Rewarding health care technology manufacturers on the basis of value is important because it sends signals to them that can influence research and development and ultimately innovation.
• Health economists have long recommended that analysts seeking to inform resource allocation decisions approximate an intervention’s value in terms of incremental cost per QALY gained (or the similar disability-adjusted life-year used commonly in global health evaluations).
• QALYs may not always fully capture the health (or well-being) of patients, or incorporate individual or community preferences about the weight to be given to health gain—for example, about disease severity, equity of access, or unmet need.

An Overview of Value, Perspective, and Decision Context [2]

• Because individuals vary in terms of their preferences for health care versus other goods, partly because of varying incomes, and in terms of their preferences for different health outcomes (e.g., survival vs. quality of life), for any specific health care technology, there will be a distribution of valuations in a population.
• Insurers—both private and public—act as agents on behalf of their enrollees who are potential patients by obtaining or providing access to health care technologies.
• Given that most medical care is purchased indirectly via health insurance, individuals do not directly face prices, and their agents (insurers and providers) acting on their behalf must assess value.
• CEA, by relating an intervention’s cost to its effectiveness (in terms of some change in health) in a ratio, is thus a standard approach to measuring the net value of a health care intervention.
• Existing guidelines for CEA emphasize the importance of clearly specifying the perspective from which the analysis is undertaken. Relevant perspectives may include, among others: 1) the typical health plan enrollee, 2) the patient, 3) the health plan manager, 4) the provider, 5) the technology manufacturer, 6) the specialty society, 7) government regulators, or 8) society as a whole. A valid and informative CEA could be conducted from the perspective of any of these stakeholders, depending on the purpose of the analysis.
• The five recent value frameworks that motivated this STF vary in the decisions that are being informed by the valuation, ranging from coverage, access, and pricing to defining appropriate clinical pathways, and to supporting provider-clinician shared decision making.
• This economic concept of value does not depend on whether value is being measured within a market-based or a single-payer health care system. Health economics and outcomes researchers generally measure value using the tool of CEA with the QALY as the health gain measure.
• Information about value is, however, used differently in different types of health care systems and by different stakeholders in different decision contexts.
• Payers may wish to use valuation by CEA to support coverage decisions as well as negotiations with manufacturers over a "value-based price." A health economics approach is most relevant to this decision context, and thus is the focus of this report.
• Specialty societies (such as the American College of Cardiology) or other organizations (such as the National Comprehensive Cancer Network or the American Society of Clinical Oncology) may use CEA or other value frameworks to design appropriate clinical pathways or to support shared clinical decision making.
• Each of these value frameworks must be evaluated in its own decision context for its own objectives.
• In market-based systems, the individual—wearing the two hats of the patient and the plan enrollee (i.e., a potential patient)—tends to be the ultimate decision maker, but individuals make these decisions with the assistance of agents—the insurers and providers.
• CEA can be patient-centric in that valuation can consider the impact of specific disease attributes on patients’ length of survival and quality of life.
• In a market-based system, decision making is more decentralized. Consumers making decisions about the purchase of private health insurance or out-of-pocket spending may vary in their objectives and preferences. Thus, they will choose among different health plans that will have different willingness-to-pay thresholds for QALYs and so different cost-effectiveness thresholds.

**Defining Elements of Value in Health Care [3]**

• The underlying concept of value from a health economic perspective is typically measured using CEA. The cost-effectiveness of a medical technology is always calculated relative to alternative choices. For this reason, CEA focuses on incremental costs and incremental benefits.
• As recommended by the Second Panel on Cost-Effectiveness in Health and Medicine, a wide range of costs or cost savings—present and future—should be considered, so long as they result directly from the interventions of interest.
• Benefit is measured from the perspective of the patient (or potential patient) given the health care technology in question. Ideally, we would have some way of capturing all these changes in terms of a common unit.
• To solve this problem, health economists have developed the concept of the QALY, which can in principle be used to measure the health benefit of any technology, regardless of the disease it treats.
• QALYs and costs often form the basis of value assessments on the basis of CEA. Nevertheless, QALYs capture only a subset of benefits that may be produced by a health care intervention. This framework neglects numerous alternative aspects of benefits that should also be considered.
• Despite its challenges, the QALY remains the most accepted measure for capturing the incremental benefit of a treatment for use in population-level decision making. However, some additional elements that may reflect value but are not normally captured in CEA with the QALY should be considered as well, depending on the perspective of the analysis.
• Productivity gains, net of consumption, should be included for societal-level perspectives in the incremental cost calculations for CEA.
• Best practice for CEA measurement includes capturing the effects (on both outcomes and costs) of real-world behavior such as adherence to an intervention.
• Some value elements, such as the value of knowing as part of diagnosis, or the psychic fear of contagion, are generally not captured but should be considered when relevant.
• Other value elements including value of insurance, severity of disease, value of hope, and real option value have been shown to modify QALY estimates, but are not commonly used in CEA. Further research to evaluate their potential for more standard use is warranted.
• Two other potential value elements—equity (beyond severity effects) and scientific spillover effects—may have individual as well as societal implications; more research on how to measure and incorporate these elements is also suggested.
• Augmenting CEA to consider these additional elements would result in a more comprehensive CEA in line with the Second Panel’s ‘Impact Inventory.’
• More research and experience are needed in the application of augmented CEA (ACEA) and the Impact Inventory. To the extent that additional elements can be valued in monetary terms, the evaluation will more closely resemble a cost-benefit analysis (CBA), which can be expressed in terms of ‘net monetary benefit.’

**Objectives, Budgets, Thresholds, and Opportunity Costs [4]**

• Use of value assessment frameworks for coverage and pricing decisions ideally requires a decision rule about what constitutes good value for money. Consistent use of a cost-effectiveness threshold, with potential consideration of other elements, can help ensure the maximization of health gain (e.g., QALYs) for a given budget.
• The choice of a threshold hinges on the decision maker’s budget, given the distribution of health care technologies: the higher the threshold, the larger must be the budget to accommodate all technologies that meet that threshold. In a health care system with a fixed budget, in the short run, the threshold should reflect the opportunity cost of the technologies displaced when new technologies are introduced.
• Thresholds and budgets used to make coverage decisions from a payer perspective should—to the extent possible—reflect consumers/taxpayers’ willingness to pay for health and financial protection ex ante, that is, preferences for insurance before individuals require health care.
• We do not recommend considering budget impact as an integral part of value assessment itself or structuring/requiring an automatic discount linked to budget impact, or introducing an inverse relationship between value and budget impact.
• Even when decision makers operate with an explicit threshold or threshold range, a deliberative process is generally followed to allow for external considerations that may modify the choice of threshold, such as equity or end-of-life concerns.

**Approaches to Aggregation and Decision Making [5]**

• Although conventional CEA and CBA are the gold standards for combining components of value and cost into a single metric, they have limitations in terms of how they address aggregation across individuals (incorporating equity, fairness, disparities, and other criteria), and in practice they do not incorporate some important components of value and cost.
• Extended CEA is a method for evaluating the distributional effects on financial risk of a medical intervention on a set of population subgroups of interest. Nevertheless, by creating separate measures of health gain and financial risk, it does not provide a single metric for treatment evaluation.
• ACEA is a proposed method for including novel elements of value in treatment evaluation. It may be expressed as a
multidimensional inventory of effects, as a cost-effectiveness ratio with additional elements included in both cost and utility, or as net monetary benefit. More research and testing are needed before this approach can be incorporated in decision making.

- Public and private insurers use deliberative decision making for payer coverage and reimbursement decisions. This can be improved by the introduction of cost-per-QALY evidence as well as by the use of more structured decision making to take account of preferences about the weight to be given to health gain compared with other attributes such as disease severity, equity of access, or unmet need.
- A transparent deliberative process can also increase the legitimacy of decision making. Currently, processes often lack transparency, and it is unclear what factors have been considered and how decisions were reached. Deliberative processes today are often informal and unstructured. Thus, without a standardized approach, key issues may be overlooked, decisions may be reached in an unstandardized way, and potential biases of decision makers may not be adequately explored.
- Multicriteria decision analysis (MCDA) provides a constructive approach to inform decision making about value, but its theory, application, and implementation need additional research. Novel methods for acquiring value weights, particularly in settings with committees acting as decision makers, may hold promise.

**Review of Recent US Value Frameworks** [6]

- The recently proposed US value frameworks can be characterized in terms of their decision contexts and perspectives, which determine how each accounts for costs and outcomes.
- The frameworks show substantial diversity in how they define and measure value, ranging from CEA to shared decision making by clinicians and patients.
- Although the frameworks have contributed in important ways to debates about value, they have been criticized on various grounds, for example, lacking conceptual foundation, omitting key components of cost or outcome given their perspectives, and not correctly considering uncertainty.
- Recent frameworks also vary considerably in whether and how they handle decision thresholds, equity, and budget concerns; our report provides some suggestions in these areas.
- Ideally, plan-level decisions would also incorporate individual and patient heterogeneity in outcomes, for example, through subgroup analysis; although recent plan-level frameworks discuss these considerations, room for improvement remains.
- Patient-oriented value frameworks can play a useful role within health plans by, for example, informing patients about the relative benefits and costs of therapies given different co-payments. Allowing consumer choice across plans can help accommodate heterogeneity in preferences.
- There are many potential areas of improvement in how value frameworks assess benefits, costs, and other factors relevant to decision making. Further research, testing, and discussion with stakeholders are needed to refine and enable such improvements for use in US health care systems.

**Recommendation I: Be explicit about decision context and perspective in value assessment frameworks.**

1. No single value assessment framework can simultaneously reflect multiple decision contexts and the perspectives of the patient, the health plan, or society as a whole. Thus, it is important for any framework to clearly articulate the value construct it represents and the perspective and decision context in which it is to be used, and to be well validated and reliable within that construct and context.
2. For societal and health plan resource allocation decisions, including coverage and reimbursement decisions, the perspective used should reflect, at a minimum, those who ultimately pay for care, including, for example, enrollees, employees, and taxpayers.
3. Well-designed patient-level frameworks can help guide shared decision making for treatment choices among the clinically appropriate options that have been approved for coverage so that patients and their providers can consider and weight factors most relevant to patient preferences and constraints.

**Recommendation II: Base health plan coverage and reimbursement decisions on an evaluation of the incremental costs and benefits of health care technologies as is provided by CEA.**

1. A central tenet in economics is to compare incremental costs and benefits in decision making. CEA and, in particular, cost-per-QALY analysis have many demonstrated strengths—and some recognized limitations; they are well established in health economics and used by decision makers in health systems worldwide.
2. Value assessment frameworks that focus on health plan coverage and reimbursement decisions should consider CEAs, as measured by cost per QALY, as a starting point to inform payer and policymaker deliberations. In many instances, the cost-per-QALY metric can serve well as the core component of these assessments.
3. Elements of costs and benefits not normally included in CEA that affect individual well-being (such as severity of illness, equity, and risk protection) may be relevant for some health plan decisions; more research is, however, needed on how best to measure and include them in decision making.

**Recommendation III: Develop value thresholds to serve as one important input to help guide coverage and reimbursement decisions.**

1. Payers—as agents for plan funders and patients—should consider decision rules guided by what they consider good value for money given their opportunity cost and budget constraints. Consistent use of a value threshold, such as cost-per-QALY limits or ranges, with potential consideration of other elements, can help to achieve maximum health gain and individual well-being for the available resources.
2. In the pluralistic US health care system, different health plans could use different thresholds or decision rules across or within plans for different types of patients, reflecting the differing generosity of their budgets and implying different levels of access to technologies. Equity, severity of illness or disability, and other considerations may alter thresholds in certain situations.
Recommendation IV: Manage budget constraints and affordability on the basis of cost-effectiveness principles

1. Budget impact analysis should not be an integral part of value assessment per se, but can play a role in addressing budget constraints and affordability.
2. Issues related to budget constraints and affordability of health care technology are most efficiently addressed in the short-term by considering: 1) the adjustment costs of reducing spending on, or replacing, existing technologies; 2) the health and cost impact of delaying or staging implementation of new technologies; and 3) the cost-effectiveness ratios of existing technologies relative to that of the innovation.
3. Over time, the availability of cost-effective new technologies may alter the desired amount of health care spending.

Recommendation V: Test and consider using structured deliberative processes for health plan coverage and reimbursement decisions

1. No existing method completely or perfectly solves the problems of aggregating cost and benefit information across individuals to a population level for benefit plan decision making or of combining multiple elements of value into a single-value metric for individuals. Thus, pragmatic approaches are needed.
2. Certain health care decisions, such as decisions to cover and pay for new technologies, can benefit from using deliberative processes that consider CEA along with other relevant decision criteria.
3. Deliberative processes for value assessment should consider using explicit frameworks such as ACEA and MCDA that emphasize structure and transparency.
4. MCDA models using individual patient-specific value weights could be developed to help patients choose among available medical interventions—those chosen for coverage by their health plan—using both their own value weights and their out-of-pocket costs.

Recommendation VI: Explore and test novel elements of benefit to improve value measures that reflect the perspectives of both plan members and patients

1. We encourage development of a more comprehensive economic evaluation that could include novel elements of value—such as insurance value, real option value, value of hope, scientific spillovers, and others—and could ultimately provide for more efficient resource allocation within the health sector and between health and non-health-related spending. More research is needed on measuring the additional value provided by—and the willingness to pay for—these novel elements.
2. More research is needed on MCDA development and use, particularly for generating value weights and thresholds, as compared with other approaches. Alternative approaches for estimating value weights and thresholds in MCDA should be tested and compared both for methodological soundness and for practical implementation factors (e.g., ease of use and reliability). Testing of MCDA models should include comparisons of their resource allocation implications with those of conventional or ACEA-based decision making as well as those of other decision approaches.
3. Payers serve as agents for their plan members who both pay premiums and become patients. Obtaining input on the value of health benefits from members of health plans, informed by patient experience, is central to the validity of value measures.

Source of financial support: The authors did not receive any funding for this work other than reimbursement from ISPOR for travel expenses, as needed, for two Special Task Force meetings.

REFERENCES